Naphthyridine Compounds for Fast-Acting Antidepressant Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant treatments for depression have a slow onset of action, limited response rate, and are associated with significant side effects, necessitating a need for faster-acting and more effective therapies that address symptoms such as fatigue, disturbed sleep, and cognitive impairments.
Innovation Solution
Development of naphthyridine compounds that act as modulators of the histamine H3 receptor and serotonin transporter, combining H3 receptor antagonism with serotonin reuptake inhibition to enhance serotonin levels in the synaptic cleft, thereby improving antidepressant efficacy and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If current antidepressant treatments are used, then depression can be treated, but the onset of action is slow
Solution Approach 1:
The patent combines H3 receptor antagonism and SERT inhibition into a single dual-action compound. The compound simultaneously blocks H3 receptors to increase histamine release (promoting wakefulness and reducing fatigue) and inhibits serotonin reuptake to increase synaptic serotonin levels, thereby achieving both immediate symptomatic relief and antidepressant effects with a faster onset of action compared to monotherapy approaches
2Reliability
If MAO inhibitors are used, then depression can be treated, but dangerous side effects occur
Solution Approach 1:
The patent changes the mechanism of action from MAO inhibition to H3 antagonism combined with SERT inhibition. This parameter change in the pharmacological approach achieves antidepressant effects through a different biochemical pathway that avoids the dangerous side effects associated with MAO inhibitors, such as hypertensive crisis and severe interactions with dietary tyramine
3Reliability
If TCAs are used, then depression can be treated, but numerous unwanted side effects occur due to complex pharmacological activities
Solution Approach 1:
The patent applies local quality by achieving high selectivity for H3 receptors and SERT while minimizing affinity for other receptor types. The compound is designed to specifically target H3 receptors in the CNS to modulate neurotransmitter release and selectively inhibit SERT to increase serotonin availability, thereby producing antidepressant effects with a much cleaner side effect profile compared to the broad-spectrum action of TCAs
4Object-affected harmful factors
If SSRIs are used, then depression can be treated with milder side effects, but the response rate is limited and onset remains slow
Solution Approach 1:
The patent merges H3 receptor antagonism with SERT inhibition in a single compound. The H3 antagonism component promotes wakefulness, reduces fatigue, and enhances cognitive function through increased histamine and other neurotransmitter release, while the SERT inhibition component increases synaptic serotonin levels. This combination provides both immediate symptomatic relief and sustained antidepressant effects, achieving a higher response rate and faster onset while maintaining a favorable side effect profile
Data Source
AI summary
Certain naphthyridine compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.